Collagen Solutions PLC Hardman research: Focused scalable growth

TIDMCOS

Collagen Solutions PLC

19 July 2016

Hardman research: Focused scalable approach to growth

Hardman & Co research report: Focused scalable approach to growth opportunities

Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, in vitro diagnostics, and regenerative medicine. New leadership has formed a global commercialisation team and introduced a number of initiatives to build on the strong base business clearly visible in the 2016 results, and execute on a scalable growth strategy. COS is also establishing a pipeline of finished devices, such as ChondroMimetic, to add incremental value to the business. These initiatives are enhancing significantly the value of the company which is not being reflected in the current share price.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/19-07-16-focused-scalable-approach-to-growth-opportunities

 
 To contact us:      Contact: Martin Hall mh@hardmanandco.com 
  Hardman & Co        Gregoire Pave gp@hardmanandco.com 
  11/12 Tokenhouse    Telephone: +44 20 7929 3399 
  Yard                Follow us on Twitter @HardmanandCo 
  London 
  EC2R 7AS

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGMGMNVRZGVZM

(END) Dow Jones Newswires

July 19, 2016 02:15 ET (06:15 GMT)

Grafico Azioni Healthcare Inv (LSE:HIO)
Storico
Da Dic 2024 a Gen 2025